Tuesday, May 24, 2011
Santarus Inc., of San Diego, reported that an open-label study of Rhucin (recombinant human C1 inhibitor) for angioedema supported safety and efficacy conclusions from earlier studies. The data covered 57 patients who received repeat treatment with Rhucin for 194 acute angioedema attacks. The study was an extension of one of two randomized, controlled trials forming the basis for regulatory approval in Europe. The results were presented at the C1 Inhibitor Deficiency Workshop in Budapest, Hungary.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.